OBJECTIVE: Chemerin is an adipocyte-secreted hormone and has recently been associated with obesity and the metabolic syndrome. Although studies in rodents have outlined the aspects of chemerin's function and expression, its physiology and expression patterns are still to be elucidated in humans. METHODS: To evaluate for any day/night variation in chemerin secretion, we analyzed hourly serum samples from six females in the fed state. To examine whether energy deprivation affects chemerin levels, and whether this could be mediated through leptin, we analyzed samples from the same subjects in the fasting state while administering either placebo or leptin. To evaluate for any potential dose-effect relationship between leptin and chemerin, we administered increasing metreleptin doses to five females. A tissue array was used to study the expression of chemerin in different human tissues. Ex vivo treatment of human fat explants from three subjects with leptin was carried out to evaluate for any direct effect of leptin on adipocyte chemerin secretion. RESULTS: Chemerin does not display a day/night variation, while acute energy deprivation resulted in a significant drop in circulating chemerin levels by ∼42%. The latter was unaltered by metreleptin administration, and leptin administration did not affect the secretion of chemerin by human adipose tissue studied ex vivo. Chemerin was expressed primarily in the pancreas and liver. Chemerin receptor showed increased expression in the lymph nodes and the spleen. CONCLUSIONS: We outline for the first time chemerin expression and physiology in humans, which are different from those in mice.
OBJECTIVE:Chemerin is an adipocyte-secreted hormone and has recently been associated with obesity and the metabolic syndrome. Although studies in rodents have outlined the aspects of chemerin's function and expression, its physiology and expression patterns are still to be elucidated in humans. METHODS: To evaluate for any day/night variation in chemerin secretion, we analyzed hourly serum samples from six females in the fed state. To examine whether energy deprivation affects chemerin levels, and whether this could be mediated through leptin, we analyzed samples from the same subjects in the fasting state while administering either placebo or leptin. To evaluate for any potential dose-effect relationship between leptin and chemerin, we administered increasing metreleptin doses to five females. A tissue array was used to study the expression of chemerin in different human tissues. Ex vivo treatment of human fat explants from three subjects with leptin was carried out to evaluate for any direct effect of leptin on adipocyte chemerin secretion. RESULTS:Chemerin does not display a day/night variation, while acute energy deprivation resulted in a significant drop in circulating chemerin levels by ∼42%. The latter was unaltered by metreleptin administration, and leptin administration did not affect the secretion of chemerin by humanadipose tissue studied ex vivo. Chemerin was expressed primarily in the pancreas and liver. Chemerin receptor showed increased expression in the lymph nodes and the spleen. CONCLUSIONS: We outline for the first time chemerin expression and physiology in humans, which are different from those in mice.
Authors: Ole-Petter R Hamnvik; Xiaowen Liu; Michael Petrou; Huizhi Gong; John P Chamberland; Esther H Kim; Costas A Christophi; Stefanos N Kales; David C Christiani; Christos S Mantzoros Journal: Metabolism Date: 2010-11-05 Impact factor: 8.694
Authors: Elizabeth Sienkiewicz; Faidon Magkos; Konstantinos N Aronis; Mary Brinkoetter; John P Chamberland; Sharon Chou; Kalliopi M Arampatzi; Chuanyun Gao; Anastasia Koniaris; Christos S Mantzoros Journal: Metabolism Date: 2011-07-07 Impact factor: 8.694
Authors: Kiymet Bozaoglu; Joanne E Curran; Claire J Stocker; Mohamed S Zaibi; David Segal; Nicky Konstantopoulos; Shona Morrison; Melanie Carless; Thomas D Dyer; Shelley A Cole; Harald H H Goring; Eric K Moses; Ken Walder; Michael A Cawthorne; John Blangero; Jeremy B M Jowett Journal: J Clin Endocrinol Metab Date: 2010-03-17 Impact factor: 5.958
Authors: Sharon H Chou; John P Chamberland; Xiaowen Liu; Giuseppe Matarese; Chuanyun Gao; Rianna Stefanakis; Mary T Brinkoetter; Huizhi Gong; Kalliopi Arampatzi; Christos S Mantzoros Journal: Proc Natl Acad Sci U S A Date: 2011-04-04 Impact factor: 11.205
Authors: Andrey Loboda; Walter K Kraft; Bernard Fine; Jeffrey Joseph; Michael Nebozhyn; Chunsheng Zhang; Yudong He; Xia Yang; Christopher Wright; Mark Morris; Ira Chalikonda; Mark Ferguson; Valur Emilsson; Amy Leonardson; John Lamb; Hongyue Dai; Eric Schadt; Howard E Greenberg; Pek Yee Lum Journal: BMC Med Genomics Date: 2009-02-09 Impact factor: 3.063
Authors: Jesse W Lloyd; Kristin A Evans; Kristy M Zerfass; Michael E Holmstrup; Jill A Kanaley; Stefan Keslacy Journal: Diabetes Metab Syndr Date: 2015-05-05
Authors: M G M Wolfs; N Gruben; S S Rensen; F J Verdam; J W Greve; A Driessen; C Wijmenga; W A Buurman; L Franke; L Scheja; D P Y Koonen; R Shiri-Sverdlov; T W van Haeften; M H Hofker; J Fu Journal: Nutr Diabetes Date: 2015-02-09 Impact factor: 5.097
Authors: Paul Horn; Uta Barbara Metzing; Ricardo Steidl; Bernd Romeike; Falk Rauchfuß; Christoph Sponholz; Daniel Thomas-Rüddel; Katrin Ludewig; Andreas L Birkenfeld; Utz Settmacher; Michael Bauer; Ralf Alexander Claus; Christian von Loeffelholz Journal: Crit Care Date: 2016-02-12 Impact factor: 9.097